Introduction
Immune checkpoint inhibitors (ICIs) have significantly improved outcomes across multiple advanced cancers. However, treatment response remains highly heterogeneous and reliable predictive biomarkers are still not available. The gut microbiome has emerged as a key modulator of anti-tumor immunity, influencing immune priming and response to ICIs. Antibiotics, commonly prescribed in oncological settings, may disrupt microbiome composition and function, potentially impairing immunotherapy efficacy. While meta-analytic evidence suggests a detrimental association between antibiotic exposure and survival outcomes, prospective longitudinal data integrating clinical and microbiome endpoints are still limited.
Aims & Methods
The IMAGE study is an ongoing observational longitudinal cohort designed to investigate the impact of antibiotic exposure on clinical outcomes and gut microbiome dynamics in patients initiating ICIs for advanced epithelial cancers (including endometrial and cervical cancers, non small cell lung cancer, melanoma, renal cell carcinoma, hepatocellular carcinoma, colorectal cancer, cholangiocarcinoma and gastric cancer). Adult patients eligible for ICI therapy are enrolled prior to treatment initiation and followed for 12 months. Stool samples and comprehensive clinical metadata -including antibiotic exposure- are collected at baseline and at predefined timepoints (90, 180, 270, and 360 days), as well as during unscheduled visits and stool sample collection in case of antibiotic use. The primary outcome is 12-month progression-free survival (PFS). Secondary outcomes include overall survival (OS), objective response rate (ORR), adverse events, and microbiome composition. Microbiome sequencing and computational analyses will assess associations between antibiotic exposure, microbial signatures, and clinical outcomes.
Results
As of April 2026, 89 patients have been enrolled (median age 62 years; 66.3% female). The most represented tumor types were endometrial (27%), cervical (25%), and non small cell lung cancer (19%). Most patients received PD-1 inhibitors (73%). Antibiotic exposure occurred in 43.8% of patients, with beta-lactams being the most frequently prescribed class (63.3%). The observed prevalence of antibiotic exposure was broadly consistent with previously published real-world cohorts of patients receiving ICIs. The most common indications were respiratory (31%) and urinary tract infections (16%).
Preliminary oncological outcomes (available in 44 patients) showed:
- Progressive disease was more frequent in antibiotic-exposed patients (8 vs 4)
- Complete responses were more frequent in non-exposed patients (4 vs 1)
- Tumor reduction occurred in both groups, with a higher number of responses among non-exposed patients (14 vs 8)
Adverse events were more common among antibiotic-exposed patients (51% vs 28%). Seven deaths (7.9%) were observed, with 57% occurring in patients previously exposed to antibiotics.
Microbiome sequencing and integrative bioinformatic analyses are currently ongoing and will be reported upon completion (results will be ready for UEG week in October -in case of acceptance-).
Conclusion
Preliminary data from the IMAGE study suggest that antibiotic exposure may be associated with worse clinical outcomes and increased toxicity in patients receiving ICIs, supporting findings from prior meta-analyses. The integration of longitudinal microbiome profiling will provide further insights into the biological mechanisms underlying this association and may help identify microbiome-based biomarkers to optimize patient stratification and therapeutic strategies.
References
1. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97-103. doi:10.1126/science.aad3297
2. Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 2018;359(6371):104-108. doi:10.1126/science.aad3293
3. Routy B, Gopalakrishnan V, Daillère R, et al. The gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science. 2018;359(6371):91-97. doi:10.1126/science.aad1329
4. Derosa L, Routy B, Fidelle M, et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell
carcinoma patients. Eur Urol. 2020;78(2):195-206. doi:10.1016/j.eururo.2020.04.006
5. Crespin E, Lescure X, Lagneaux C, et al. Antibiotic exposure and clinical outcomes in patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis. J ImmunoTher Cancer. 2020;8(1):e001271. doi:10.1136/jitc-2020-001271
Disclosure
CONFLICTS OF INTEREST: G.I. has received personal fees for acting as speaker for Biocodex, Danone, Sofar, Malesci, Metagenics and Tillotts Pharma, and for acting as consultant and/or advisor for Ferring Therapeutics, Giuliani, Malesci and Tillotts Pharma. A.G. reports personal fees for consultancy from Eisai Srl, 3PSolutions, Real Time Meeting, Fondazione Istituto Danone, SinergieSrl, Board MRGE and Sanofi SpA personal fees for acting as a speaker for Takeda SpA, AbbVie and Sandoz SpA and personal fees for acting on advisory boards for VSL3 and Eisai. All other authors have no conflicts of interest to disclose.
The authors thank SEERAVE Foundation for its support of the IMAGE study.